Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Share Price Should Tripple to Quadruple from now until ASCO

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Apr 27, 2023 1:29pm

84 Views

Post# 35417444

RE:Share Price Should Tripple to Quadruple from now until ASCO

Just love all the talk about ALL the other buyouts for jillions of dollars.... like this means anything to oncy. I wonder how much some of you get paid per post... must be a lot cause your sure posting alot of garbage... I guess all this makes everyone feel good.

<< Previous

Bullboard Posts

Next >>

NervGen: Are amazing human trial results leaking out?